Biblio Discovery — Demo Discovery Service

371 results

Showing 1–20 · 0.37 seconds · RSS

Journal

Therapeutic Advances in Drug Safety

Scopus

ISSN 2042-0994 · SAGE Publishing · 371 articles in the index

  1. Journal Article

    Drug interactions in rheumatoid arthritis: a disparity between electronic database prediction and real-world co-prescription with different large language models

    Tonson Lalitkanjanakul; Dhanesh Pitidhammabhorn; Natnicha Jakramonpreeya et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that often requires multi-drug regimens, which can increase the risk of drug–drug interactions (DDIs). Objective: To determine whether polypharmacy contributes to potential DDIs in patients with RA. Design: A retrospective…

  2. Journal Article

    Comparative pharmacovigilance of glycaemic adverse-event reporting for alpelisib and capivasertib: A disproportionality analysis of the FDA adverse event monitoring system

    Yongjian Liu; Hao Zhong; Xingjun Huang et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background Alpelisib and capivasertib inhibit adjacent nodes of the phosphatidylinositol 3-kinase/protein kinase B pathway and disrupt glucose homeostasis. Their overlapping fulvestrant-based treatment contexts support comparison despite different biomarker eligibility. Objectives To compare the…

  3. Journal Article

    Risk of infection with potassium-competitive acid blockers: A systematic review with restricted quantitative synthesis

    Ah Young Lee MD, MSc; Kwanjoo Lee MD, MSc; Sun Jae Moon MD et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background The risk of Clostridioides difficile infection (CDI) related to potassium-competitive acid blocker (P-CAB) use remains uncertain. Objective This study aimed to systematically synthesize available evidence on CDI risk among P-CAB users. Design Systematic review with restricted…

  4. Journal Article

    Detection of clinically significant drug-drug interactions in serotonin syndrome: a multisource real-world data and pharmacovigilance study

    Shanshan Xu; Zhihui Song; Dong Wang et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Serotonin syndrome (SS) is a potentially life-threatening condition increasingly driven by complex drug-drug interactions (DDIs) as serotonergic agents expand beyond psychiatry into pain management and infectious disease treatment. Current clinical decision support tools often exhibit…

  5. Journal Article

    A descriptive, retrospective analysis of the quality of spontaneous adverse event reporting to the Côte d’Ivoire Pharmaceutical and Regulatory Authority and its impact on the causality assessment

    Mamadou Kamagaté; Viviane Jusot; Diaby Mory et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: In Côte d’Ivoire, pharmacovigilance is not a routine activity in most healthcare facilities and many healthcare professionals have limited knowledge of pharmacovigilance methods. Objectives: This study aimed to evaluate the quality of adverse event (AE) reports submitted to the central…

  6. Journal Article

    Comparison of pharmacovigilance and mechanism analysis of the vascular toxicity caused by platin-based chemotherapy: integration of FAERS analysis, network pharmacology, and endothelial validation

    Yuzhu Chen; Chunhua Wang; Peng Jiang et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Understanding of the possible vasoactive toxicities associated with platinum‑containing chemotherapeutic drugs for solid tumors remains limited. Objectives: This study comprehensively identifies the vessel-threatening effects of cisplatin (CDDP), carboplatin (CBP), and oxaliplatin (OXA)…

  7. Journal Article

    Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data

    Yujie Lin; Jing Yao

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Belimumab is a biologic agent used in the treatment of systemic lupus erythematosus (SLE). However, its safety profile during pregnancy has not been fully established, and real-world evidence regarding its association with adverse pregnancy outcomes remains limited. Objectives: To…

  8. Journal Article

    Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study

    Varalee Yodsurang; Krit Wattanathum; Thanate Srimatimanon et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: While bleeding is an inherent risk of all anticoagulant therapies, individual susceptibility varies considerably. Rivaroxaban, a direct oral anticoagulant widely used for thromboembolic prevention, is associated with substantial interindividual variability in bleeding risk, posing an…

  9. Journal Article

    Absence of pharmacovigilance signals for bleeding events associated with warfarin-SSRI drug interactions: a comparative analysis of FAERS and CVARD databases

    Pan Zhang; Siyuan Cheng; Junlin Diao et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Warfarin and selective serotonin reuptake inhibitors (SSRIs) are frequently co-prescribed in clinical practice, particularly among elderly patients with comorbid cardiovascular and psychiatric conditions. Although theoretical pharmacological mechanisms suggest an increased bleeding risk…

  10. Journal Article

    An assessment of medication errors and associated factors to strengthen patient safety practices in a tertiary hospital in Cameroon

    Alberic Ndonku Signang PharmD, MMSCI, PhD; Mbohjim Othniel Mobit MEd; Taneh Yvonne Shee et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background Medication errors contribute significantly to patient harm and healthcare costs worldwide. However, there is limited evidence on their prevalence and characteristics in Cameroon. Objective To estimate the prevalence, types, and associated factors of medication errors in a tertiary…

  11. Journal Article

    Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study

    Wei-Yang Xue; Xi Li; Wen-Ting Li et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Anti-β-amyloid monoclonal antibodies provide a disease-modifying treatment approach for Alzheimer’s disease, but post-marketing safety concerns remain, particularly amyloid-related imaging abnormalities (ARIA). Real-world studies have mainly described adverse event spectra and…

  12. Journal Article

    Factors associated with medication administration errors in hospitalized pediatric patients: A scoping review

    Claudia Lorena Motta Robayo; Jonathan Martínez Pinto; Bryan Tabango Goyes et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background Medication errors are a leading preventable cause of harm in hospitalized children. The pediatric population is particularly vulnerable due to weight-based dosing requirements, developmental pharmacokinetic variability, and limited capacity for self-advocacy. Objectives To map and…

  13. Journal Article

    Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations

    Nidhi Shrivastava; Santosh Laxman Gaonkar; Fayaz Shaik Mahammad

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are a standard treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer, but differences in toxicity, monitoring requirements, and…

  14. Journal Article

    Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literature

    Lucie Regaldo-Saint Blancard; Simon Pernot; Marianne Fonck et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Oxaliplatin commonly induces acute, transient peripheral neurotoxicity, most often presenting as cold-induced paresthesia. Ocular adverse events are rare and poorly understood. This case describes a rare, reproducible transient monocular visual field loss associated with oxaliplatin exposure. We…

  15. Journal Article

    Evaluation of digoxin dosing and therapeutic drug monitoring in adult patients receiving continuous venovenous hemodiafiltration

    Madison P. Nordin PharmD, MBA; Jenna F. Cox PharmD, BCPS, BCCCP, FCCM; Bryan L. Love PharmD, MPH, FCCP et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background Digoxin dosing guidance during continuous renal replacement therapy (CRRT) is scarce, relying on two case reports with pharmacokinetic modeling not subsequently validated by TDM and expert opinion. Objective To examine varying digoxin dosing regimen effects on serum digoxin…

  16. Journal Article

    Sex-specific risk factors for genital infections associated with SGLT2 inhibitors in type 2 diabetes: a retrospective cohort study and disproportionality analysis using JADER

    Ayami Kajiwara-Morita; Sawa Kugimoto; Kentaro Oniki et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Genital infections are notable adverse events that may lead to nonadherence to or discontinuation of sodium-glucose cotransporter 2 (SGLT2) inhibitors, essential agents in the management of type 2 diabetes (T2D). Although sex differences in incidence rates have been reported, the risk…

  17. Journal Article

    Team approach to polypharmacy evaluation and reduction for general practice patients with dementia: the Australian TAPERDem study

    Christopher Etherton-Beer; Amy Theresa Page; Hui Wen Quek et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Polypharmacy is common in people with dementia but may be insufficiently tailored to personal preferences and goals, particularly in the presence of a life-limiting condition. Objectives: To evaluate the effectiveness of pharmacists working with general practitioners (GPs) to optimise…

  18. Journal Article

    Sequential analysis for post-marketing drug safety surveillance using routinely collected electronic healthcare data: a scoping review

    Yixin Sun; Qian Ding; Hongting Nie et al.

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: Routinely collected electronic healthcare data have created new opportunities for active, near real-time post-marketing drug safety surveillance. Sequential analysis offers a natural framework for periodic signal detection as data accrue and may facilitate earlier identification of…

  19. Journal Article

    Development and validation of a MedDRA-based signal detection construct for drug-induced neurobehavioral impairment

    Christopher D. Breder

    Therapeutic Advances in Drug Safety, Vol. 17 · 2026 · English · DOAJ Scopus

    Background: The FDA’s Guidance for an industry evaluating drug effects on the ability to operate a motor vehicle describes the need to evaluate drug-induced neurobehavioral impairment. However, the guidance does not provide instruction or the means to implement the analysis. Objective: The proposed…